MCID: BCL017
MIFTS: 61

B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for B-Cell Lymphoma

MalaCards integrated aliases for B-Cell Lymphoma:

Name: B-Cell Lymphoma 11 19 28 14 36 75
Lymphoma, B-Cell 19 43 38
B-Cell Lymphomas 75 14 71
B-Cell Lymphocytic Neoplasm 11
B-Cell Lymphoma Nos 33
Lymphoma B-Cell 53

Classifications:



External Ids:

Disease Ontology 11 DOID:707
MeSH 43 D016393
NCIt 49 C3457
SNOMED-CT 68 109979007
ICD10 31 C85.1
ICD11 33 1275688866
UMLS 71 C0079731

Summaries for B-Cell Lymphoma

GARD: 19 "B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the ""B-cells"" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders."

MalaCards based summary: B-Cell Lymphoma, also known as lymphoma, b-cell, is related to marginal zone b-cell lymphoma and lymphoma, mucosa-associated lymphoid type. An important gene associated with B-Cell Lymphoma is MIR17 (MicroRNA 17), and among its related pathways/superpathways are Cytokine Signaling in Immune system and NF-kappaB Signaling. The drugs Lomustine and Rivoceranib have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone marrow, and related phenotypes are endocrine/exocrine gland and cellular

Disease Ontology: 11 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia 75 B-cell lymphoma: The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are "blood cancers" in the lymph... more...

B-cell lymphomas: Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Related Diseases for B-Cell Lymphoma

Diseases in the B-Cell Lymphoma family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1586)
# Related Disease Score Top Affiliating Genes
1 marginal zone b-cell lymphoma 33.9 MYC MALT1 IRF4 CCND1 BCL6 BCL2
2 lymphoma, mucosa-associated lymphoid type 33.8 MYC MALT1 IRF4 CCND1 BCL6 BCL2
3 diffuse large b-cell lymphoma 33.7 PRDM1 MYC MIR17 IRF4 HOTAIR BCL6
4 primary mediastinal b-cell lymphoma 33.6 MYC IRF4 BCL6 BCL2
5 intravascular large b-cell lymphoma 33.5 BCL6 BCL2
6 high-grade b-cell lymphoma double-hit/triple-hit 33.5 MYC IRF4 BCL6 BCL2
7 relapsed/refractory diffuse large b-cell lymphoma 33.4 MYC BCL6 BCL2
8 diffuse large b-cell lymphoma activated b-cell type 33.3 MYC IRF4 BCL6 BCL2
9 nodal marginal zone lymphoma 33.2 MALT1 IRF4 BCL6 BCL2 BCL10
10 plasmablastic lymphoma 33.2 PRDM1 MYC IRF4 BCL6
11 lymphoma 33.2 PVT1 PRDM1 MYC MCL1 MALT1 IRF4
12 follicular lymphoma 33.1 MYC MCL1 IRF4 CCND1 BCL6 BCL2L1
13 gray zone lymphoma 33.1 IRF4 BCL6
14 lymphoma aids related 32.9 MYC BCL6
15 splenic marginal zone lymphoma 32.9 MALT1 CCND1 BCL6
16 chronic lymphocytic leukemia/small lymphocytic lymphoma 32.8 CCND1 BCL6 BCL2
17 reticulosarcoma 32.8 MYC BCL6 BCL2
18 burkitt lymphoma 32.7 TP53COR1 PVT1 PRDM1 MYC IRF4 BCL6
19 lymphoma, hodgkin, classic 32.7 PVT1 MIR20A MCL1 IRF4 BCL6 BCL3
20 monoclonal gammopathy of uncertain significance 32.6 MYC IRF4 CCND1
21 lymphoma, non-hodgkin, familial 32.5 MYC MIR20A MIR17 MCL1 MALT1 IRF4
22 b-cell non-hodgkin lymphoma 32.2 PRDM1 BCL6
23 central nervous system lymphoma 32.2 MYC IRF4 BCL6 BCL2
24 gastric lymphoma 32.2 MALT1 IRF4 BCL6 BCL2 BCL10
25 breast lymphoma 32.0 IRF4 BCL6 BCL2
26 acquired immunodeficiency syndrome 31.9 MYC CCND1 BCL6 BCL2
27 lymphoplasmacytic lymphoma 31.9 IRF4 CCND1 BCL6 BCL2
28 leukemia, acute lymphoblastic 31.9 MYC MIR17 MCL1 IRF4 BCL6 BCL2L1
29 anaplastic large cell lymphoma 31.9 MCL1 BCL3 BCL2L1 BCL2
30 testicular lymphoma 31.9 IRF4 BCL6 BCL2
31 richter's syndrome 31.9 MYC BCL6 BCL2
32 peripheral t-cell lymphoma 31.9 MIR17 MCL1 BCL6 BCL3 BCL2
33 bone lymphoma 31.8 IRF4 BCL6 BCL2
34 leukemia, chronic lymphocytic 2 31.8 MCL1 BCL3 BCL2
35 mantle cell lymphoma 31.7 MYC MIR17 MCL1 MALT1 MALAT1 IRF4
36 lung lymphoma 31.7 MALT1 IRF4 BCL6
37 gastrointestinal lymphoma 31.7 MALT1 CCND1 BCL6 BCL2 BCL10
38 peripheral nervous system disease 31.6 MYC MIR17 MCL1 CCND1 BCL2L1 BCL2
39 composite lymphoma 31.6 BCL6 BCL2
40 leukemia 31.6 MYC MCL1 HOTAIR GAS5 CCND1 BCL3
41 t-cell acute lymphoblastic leukemia 31.5 MYC MIR17 IRF4 GAS5 BCL2L1 BCL2
42 adult lymphoma 31.5 PRDM1 MYC IRF4 BCL6 BCL2
43 adult t-cell leukemia/lymphoma 31.5 MYC IRF4 BCL2
44 colon lymphoma 31.5 CCND1 BCL6 BCL2
45 leukemia, chronic lymphocytic 31.4 TP53COR1 MYC MIR20A MIR17 MCL1 IRF4
46 orofaciodigital syndrome viii 31.4 MALT1 BCL6 BCL10
47 hematologic cancer 31.4 PVT1 MIR20A MIR17 IRF4 BCL2
48 colonic benign neoplasm 31.3 MYC CCND1 BCL2L1 BCL2
49 orbit lymphoma 31.3 MALT1 BCL10
50 plasmacytoma 31.3 PVT1 PRDM1 MYC IRF4 GAS5 CCND1

Graphical network of the top 20 diseases related to B-Cell Lymphoma:



Diseases related to B-Cell Lymphoma

Symptoms & Phenotypes for B-Cell Lymphoma

MGI Mouse Phenotypes related to B-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.96 BCL10 BCL11A BCL2 BCL2L1 BCL6 CCND1
2 cellular MP:0005384 9.93 BCL10 BCL11A BCL2 BCL2L1 BCL6 CCND1
3 no phenotypic analysis MP:0003012 9.87 BCL6 HOTAIR MALAT1 MYC PRDM1 TP53COR1
4 immune system MP:0005387 9.77 BCL10 BCL11A BCL2 BCL2L1 BCL3 BCL6
5 hematopoietic system MP:0005397 9.4 BCL10 BCL11A BCL2 BCL2L1 BCL3 BCL6

Drugs & Therapeutics for B-Cell Lymphoma

Drugs for B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 419)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
2
Rivoceranib Investigational Phase 4 811803-05-1 11315474
3 Endothelial Growth Factors Phase 4
4
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Carmustine Approved, Investigational Phase 3 154-93-8 2578
9
Blinatumomab Approved, Investigational Phase 2, Phase 3 853426-35-4
10
Pixantrone Approved, Investigational Phase 3 144510-96-3 134019
11
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
12
Chlorambucil Approved Phase 3 305-03-3 2708
13
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2 135565884
14
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704
15
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
16
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
17
Vinblastine Approved Phase 3 865-21-4 241903 13342
18
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
19
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
20
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
21
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
22
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 4112 126941
24
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
25
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
26
Etoposide Approved Phase 3 33419-42-0 36462
27
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
28
Ifosfamide Approved Phase 3 3778-73-2 3690
29
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
34
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
35
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
36
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
37
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
38
Avelumab Approved, Investigational Phase 3 1537032-82-8
39
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
40
Ofatumumab Approved Phase 3 679818-59-8
41
Idarubicin Approved Phase 3 58957-92-9 42890
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
43
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
44
Arginine Approved, Investigational, Nutraceutical Phase 3 74-79-3 6322
45
Buformin Investigational, Withdrawn Phase 2, Phase 3 692-13-7 2468
46
Tenofovir Experimental, Investigational Phase 3 147127-20-6, 202138-50-9 464205 6398764
47
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
48
Palifosfamide Investigational Phase 3 31645-39-3 100427
49
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
50 Hypoglycemic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 1807)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
3 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
4 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Unknown status NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
5 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial Unknown status NCT02992834 Phase 4
6 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
7 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
8 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) Recruiting NCT05518383 Phase 4 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
9 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Active, not recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
10 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
11 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
12 Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma Unknown status NCT02767674 Phase 3 Rituximab;Gemcitabine;Oxaliplatin;Cyclophosphamide;Epirubicin Injectable Product;Vindesine;Prednisone
13 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
14 A Phase III, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of SIBP-02 (Rituximab Biosimilar) and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL Unknown status NCT04361279 Phase 3 SIBP-02;Rituximab
15 Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT03777085 Phase 3 TQB2303;Rituximab
16 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;VP-16
17 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
18 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
19 CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma Unknown status NCT03391726 Phase 2, Phase 3
20 A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT,in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL Unknown status NCT03213977 Phase 3 R-DA-EPOCH;R-DA-EPOCH + auto-HSCT;R-CEOP90;R-CEOP90 + auto-HSCT
21 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
22 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
23 A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients Unknown status NCT03650933 Phase 3
24 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
25 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
26 Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study Unknown status NCT02871869 Phase 2, Phase 3 vindesine;cyclophosphamide;Epirubicin;prednisone tablets;Cinobufacini Tablets;Rituximab
27 Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma Unknown status NCT03018626 Phase 3 Rituximab;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Vindesine;Bleomycin
28 An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients Unknown status NCT03318835 Phase 3 Thalidomide combined with R-CHOP;R-CHOP
29 Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma Unknown status NCT03123718 Phase 3 Intrathecal methotrexate;High-dose intravenous methotrexate
30 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Unknown status NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
31 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
32 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
33 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Unknown status NCT02991638 Phase 3 Ibrutinib
34 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Unknown status NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
35 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
36 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
37 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Completed NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
38 Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association Completed NCT02128061 Phase 3 Lenalidomide;Rituximab
39 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Completed NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
40 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Completed NCT04236141 Phase 3 Polatuzumab Vedotin;Bendamustine;Rituximab;Placebo
41 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
42 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
43 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
44 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ Completed NCT03263026 Phase 3 Enzastaurin Hydrochloride
45 Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study Completed NCT00162656 Phase 3 half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
46 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
47 Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line Completed NCT01122472 Phase 3 Lenalidomide;Placebo
48 Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
49 Improving Sleep Quality, Psychosocial Functioning, and Cancer Related Fatigue With Light Therapy Completed NCT03242902 Phase 3
50 Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Completed NCT00118209 Phase 3 cyclophosphamide;doxorubicin;vincristine;prednisone;etoposide;filgrastim;pegfilgrastim

Search NIH Clinical Center for B-Cell Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ibritumomab tiuxetan
Ibrutinib
rituximab

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphoma

Genetic tests related to B-Cell Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 28

Anatomical Context for B-Cell Lymphoma

Organs/tissues related to B-Cell Lymphoma:

MalaCards : T Cells, B Cells, Bone Marrow, Nk Cells, Bone, Myeloid, Breast

Publications for B-Cell Lymphoma

Articles related to B-Cell Lymphoma:

(show top 50) (show all 35255)
# Title Authors PMID Year
1
MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. 62 46
18941111 2009
2
Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. 53 62
20428773 2010
3
Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. 53 62
20442643 2010
4
IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type. 53 62
20054341 2010
5
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. 53 62
20190733 2010
6
Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. 53 62
20331331 2010
7
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. 53 62
20303013 2010
8
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. 53 62
19889619 2010
9
Xeroderma pigmentosum skin: an immune privilege site for tumor development. 53 62
19719835 2010
10
The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma. 53 62
20459572 2010
11
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 53 62
19965662 2010
12
Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. 53 62
19714753 2010
13
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. 53 62
20371444 2010
14
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. 53 62
20371683 2010
15
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. 53 62
20122924 2010
16
CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. 53 62
20093404 2010
17
Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. 53 62
18815567 2010
18
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 53 62
20490333 2010
19
Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. 53 62
19966860 2010
20
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 53 62
20062012 2010
21
Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. 53 62
20093241 2010
22
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 53 62
20081860 2010
23
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 53 62
20004001 2010
24
Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. 53 62
20107311 2010
25
Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. 53 62
20174727 2010
26
Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. 53 62
20130454 2010
27
Deregulation of H3K27 methylation in cancer. 53 62
20104248 2010
28
Mechanisms of chromosomal rearrangement in the human genome. 53 62
20158866 2010
29
Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. 53 62
20103729 2010
30
Cancer chemoprevention locks onto a new polyamine metabolic target. 53 62
20103728 2010
31
[Correlation of Bcl-2 with immunological subtype and prognosis in diffuse large B-cell lymphoma.]. 53 62
20302777 2010
32
Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. 53 62
19857547 2010
33
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. 53 62
20023629 2010
34
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. 53 62
19965678 2010
35
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 53 62
20054396 2010
36
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. 53 62
19797725 2010
37
Blimp-1 is a tumor suppressor gene in lymphoid malignancies. 53 62
20047096 2010
38
Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. 53 62
20010689 2009
39
REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. 53 62
19289490 2009
40
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. 53 62
20016842 2009
41
Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? 53 62
19860620 2009
42
BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. 53 62
19855081 2009
43
[Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma]. 53 62
20030925 2009
44
Gene expression profiling of diffuse large B-cell lymphoma -- comparison depending on the CD21 antigen expression. 53 62
20009432 2009
45
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. 53 62
19814686 2009
46
Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. 53 62
20032398 2009
47
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 53 62
20079013 2009
48
[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children]. 53 62
20079016 2009
49
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. 53 62
19734449 2009
50
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. 53 62
19725825 2009

Variations for B-Cell Lymphoma

Expression for B-Cell Lymphoma

Search GEO for disease gene expression data for B-Cell Lymphoma.

Pathways for B-Cell Lymphoma

Pathways related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 MYC MCL1 IRF4 CCND1 BCL6 BCL2L1
2 12.46 BCL10 BCL6 IRF4 MALT1 PRDM1
3
Show member pathways
12.13 MYC CCND1 BCL2L1 BCL2
4
Show member pathways
12.04 MALT1 CCND1 BCL2L1 BCL10
5 12.03 PRDM1 MYC IRF4 CCND1 BCL6
6
Show member pathways
12.01 MYC MCL1 BCL2L1 BCL2
7
Show member pathways
11.99 MYC MCL1 MALT1 BCL2L1 BCL2 BCL10
8 11.93 PRDM1 MCL1 BCL6 BCL2
9
Show member pathways
11.9 MYC BCL2L1 BCL2
10 11.88 MYC CCND1 BCL2L1
11 11.77 MYC CCND1 BCL6 BCL2
12 11.73 MYC CCND1 BCL6 BCL2
13 11.72 MYC CCND1 BCL2
14 11.69 BCL2 BCL2L1 CCND1 MYC
15 11.68 CCND1 BCL2L1 BCL2
16 11.66 PRDM1 IRF4 BCL6
17 11.61 MALT1 BCL6 BCL10
18 11.58 BCL2 CCND1 MYC
19 11.56 IRF4 BCL6 BCL2L1
20 11.52 CCND1 BCL2L1 BCL2
21 11.5 MYC CCND1 BCL2L1
22 11.45 MYC MIR20A MIR17 CCND1
23 11.41 MYC MCL1 BCL2L1
24
Show member pathways
11.4 MYC BCL2L1 BCL2
25 11.32 MCL1 BCL2L1 BCL2
26 11.26 MYC CCND1 BCL2L1
27 11.2 MYC MCL1 IRF4 CCND1 BCL6 BCL2L1
28 11.19 IRF4 BCL2 BCL11A
29 11.18 MYC CCND1 BCL2L1
30 10.91 MYC CCND1
31 10.76 MYC CCND1
33
Show member pathways
10.34 MCL1 BCL2L1 BCL2

GO Terms for B-Cell Lymphoma

Cellular components related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Bcl-2 family protein complex GO:0097136 9.46 MCL1 BCL2L1
2 CBM complex GO:0032449 9.26 MALT1 BCL10
3 polkadots GO:0002096 8.92 MALT1 BCL10

Biological processes related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.07 BCL2 BCL2L1 BCL3 BCL6 MALT1 MCL1
2 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10.04 MCL1 BCL2L1 BCL2
3 response to cytokine GO:0034097 10.02 MCL1 BCL2L1 BCL2
4 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 10.01 BCL10 MALT1 MYC
5 cellular response to hypoxia GO:0071456 9.97 MYC MIR17 MALAT1 BCL2
6 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.93 MCL1 BCL2L1 BCL2
7 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.91 BCL2 BCL2L1 MCL1
8 negative regulation of dendritic cell apoptotic process GO:2000669 9.88 BCL2L1 BCL2
9 T-helper 2 cell differentiation GO:0045064 9.86 BCL6 BCL3
10 response to radiation GO:0009314 9.8 PRDM1 BCL2L1 BCL2
11 response to fungus GO:0009620 9.69 MALT1 BCL10
12 regulation of T cell receptor signaling pathway GO:0050856 9.65 MALT1 BCL10
13 T cell apoptotic process GO:0070231 9.63 BCL3 BCL2 BCL10
14 dendritic cell apoptotic process GO:0097048 9.62 BCL2L1 BCL2
15 regulation of apoptotic process GO:0042981 9.56 MCL1 MALT1 BCL3 BCL2L1 BCL2 BCL10
16 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.52 MIR20A MIR17
17 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.37 MIR20A MIR17
18 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 9.17 MIR17 MCL1 BCL2L1 BCL2

Molecular functions related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor binding GO:0140297 9.76 MYC BCL6 BCL3 BCL2
2 kinase activator activity GO:0019209 9.26 MALT1 BCL10
3 BH3 domain binding GO:0051434 9.1 MCL1 BCL2L1 BCL2

Sources for B-Cell Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....